| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYO7A |
| Uniprot No | Q13402 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 838-968aa |
| 氨基酸序列 | WAVLTVQAYARGMIARRLHQRLRAEYLWRLEAEKMRLAEEEKLRKEMSAKKAKEEAERKHQERLAQLAREDAERELKEKEAARRKKELLEQMERARHEPVNHSDMVDKMFGFLGTSGGLPGQEGQAPSGFE |
| 预测分子量 | 31.3kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Expression and functional characterization of MYO7A in mammalian cells" by Liu et al.**
*摘要*：研究通过HEK293细胞表达重组MYO7A蛋白，并验证其ATP酶活性及与肌动蛋白的相互作用，为研究其在内耳毛细胞中的功能提供基础。
2. **"Structural analysis of the MYO7A motor domain reveals mechanisms underlying Usher syndrome" by Watanabe et al.**
*摘要*：利用X射线晶体学解析MYO7A马达结构域的三维结构，揭示致病突变如何破坏其构象，导致Usher综合征中的听觉与视觉缺陷。
3. **"Recombinant MYO7A restores hair cell function in a zebrafish model of deafness" by Ernest et al.**
*摘要*：通过斑马鱼模型验证重组MYO7A蛋白的挽救功能，证明其可恢复突变体毛细胞的机械转导活性，支持基因治疗的潜在应用。
4. **"Interaction of MYO7A with cargo adaptors in retinal pigment epithelium" by Gibbs et al.**
*摘要*：研究重组MYO7A与视网膜色素上皮细胞中货物适配蛋白的结合特性，阐明其在胞内运输中的作用及相关眼疾的分子机制。
(注：以上文献信息为示例，实际引用请根据具体论文调整。)
MYO7A recombinant protein is derived from the MYO7A gene, which encodes myosin VIIA, a member of the myosin superfamily of actin-based motor proteins. Myosin VIIA plays critical roles in intracellular trafficking, structural organization of sensory cells, and mechanotransduction. It is particularly vital in auditory and visual systems, where mutations in MYO7A are linked to human disorders such as Usher syndrome type 1B (characterized by congenital deafness, vestibular dysfunction, and progressive retinal degeneration) and non-syndromic hearing loss.
The MYO7A protein consists of a motor domain that binds actin and hydrolyzes ATP, a neck region with IQ motifs for calmodulin binding, and a tail domain involved in cargo recognition and dimerization. Its function extends to maintaining stereocilia cohesion in inner ear hair cells and supporting melanosome transport in retinal pigment epithelium cells. Recombinant MYO7A protein is typically produced using heterologous expression systems (e.g., bacterial, insect, or mammalian cells) to study its biochemical properties, interaction partners, and disease-associated mutations. Purification often involves affinity tags (e.g., His-tag) followed by chromatography techniques.
Research on MYO7A recombinant protein has advanced understanding of its role in cellular motility, vesicle transport, and sensory cell maintenance. It serves as a tool for investigating pathogenic mechanisms, screening therapeutic compounds, and developing gene therapies for MYO7A-related disorders. Challenges persist in mimicking its native conformational states and post-translational modifications, necessitating careful selection of expression systems for functional studies.
×
